论文部分内容阅读
目的观察西酞普兰治疗肠易激综合征的疗效及不良反应。方法采用随机对照的研究方法 ,选取符合罗马Ⅲ标准的肠易激综合征(IBS)患者104例,失访2例,其余患者分为观察组(52例)及对照组(50例)。对照组给予常规内科治疗(匹维溴铵、双歧杆菌三联活菌胶囊、莫沙必利等),观察组在常规治疗基础上加西酞普兰治疗,比较两组疗效。结果治疗后观察组焦虑抑郁量表症状积分评分优于对照组,差异具有统计学意义(P<0.05)。结论西酞普兰治疗肠易激综合征患者疗效稳定,不良反应少,值得临床推广应用。
Objective To observe the efficacy and adverse reactions of citalopram in the treatment of irritable bowel syndrome. Methods According to the randomized controlled study, 104 cases of IBS who meet the criteria of Rome Ⅲ were selected and 2 cases were lost to follow-up. The remaining patients were divided into observation group (52 cases) and control group (50 cases). The control group were given conventional medical treatment (pirivirubine, Bifidobacterium triple viable capsule, mosapride and so on). The observation group was treated with citalopram on the basis of routine treatment, and the curative effect was compared between the two groups. Results After treatment, anxiety and depression scale symptom scores in the observation group were better than those in the control group, the difference was statistically significant (P <0.05). Conclusion Citalopram in treatment of irritable bowel syndrome patients with stable efficacy, fewer adverse reactions, it is worth promoting the clinical application.